Toggle Side Panel
Close search

Finerenone slows eGFR decline in patients without diabetes, Aussie research shows

Finerenone is currently approved in Australia only for patients with chronic kidney disease and type 2 diabetes.

Finerenone lowers the risk of chronic kidney disease and kidney events even in patients without diabetes, Australian research shows,

It is the first evidence that finerenone’s benefits in chronic kidney disease (CKD) extend beyond patients with diabetes, say the researchers, who published three studies this month in The New England Journal of Medicine, The Lancet and JAMA.

The New England Journal of Medicine study, a randomised trial called FIND-CKD — funded by finerenone maker Bayer — followed 1584 non-diabetic patients with CKD for three years.

Mean annual eGFR change was −3.3mL/min/1.73m² with treatment compared with −4.0mL/min/1.73m² with placebo.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .